Baseline characteristics of the study population
. | Noncases 25%-median-75% or % (n = 2,169) . | Cancer cases 25%-median-75% or % (n = 296) . | P* . | |||
---|---|---|---|---|---|---|
Follow-up time (mean years) | 5.92 | 2.85 | ||||
Age | 71-73-76 | 71-74-76 | 0.09 | |||
Gender (females; %) | 55 | 38 | <0.001 | |||
Race (Caucasian; %)† | 55 | 51 | 0.16 | |||
Site (Memphis; %)† | 50 | 48 | 0.49 | |||
Education (%) | ||||||
Less than high school | 27 | 25 | 0.30 | |||
High school | 33 | 31 | ||||
Postsecondary | 40 | 44 | ||||
Smoking status (%) | ||||||
Never | 46 | 33 | <0.001 | |||
Former | 44 | 52 | ||||
Current | 10 | 16 | ||||
Pack-years (continuous) | 0-2-27 | 0-15-43 | ||||
Comorbid conditions (%) | ||||||
Cardiovascular disease | 23 | 23 | 0.98 | |||
Diabetes | 16 | 16 | 0.91 | |||
Chronic obstructive pulmonary disease and other pulmonary diseases | 12 | 12 | 0.73 | |||
BMI | 24.1-27.0-30.2 | 24.2-27.1-30.7‡ | 0.71 | |||
Abdominal visceral fat area (cm2) | 93-129-178 | 99-138-183† | 0.08 | |||
Physical activity, kcal/wk (%) | ||||||
0-499.9 | 37 | 40 | 0.15 | |||
500-999.9 | 34 | 35 | ||||
≥1,000 | 29 | 25 | ||||
Medication use (%) | ||||||
NSAIDs | 23 | 18 | 0.04 | |||
Corticosteroids | 4 | 3 | 0.38 | |||
ACE inhibitors | 15 | 17 | 0.43 | |||
Statins | 12 | 14 | 0.34 |
. | Noncases 25%-median-75% or % (n = 2,169) . | Cancer cases 25%-median-75% or % (n = 296) . | P* . | |||
---|---|---|---|---|---|---|
Follow-up time (mean years) | 5.92 | 2.85 | ||||
Age | 71-73-76 | 71-74-76 | 0.09 | |||
Gender (females; %) | 55 | 38 | <0.001 | |||
Race (Caucasian; %)† | 55 | 51 | 0.16 | |||
Site (Memphis; %)† | 50 | 48 | 0.49 | |||
Education (%) | ||||||
Less than high school | 27 | 25 | 0.30 | |||
High school | 33 | 31 | ||||
Postsecondary | 40 | 44 | ||||
Smoking status (%) | ||||||
Never | 46 | 33 | <0.001 | |||
Former | 44 | 52 | ||||
Current | 10 | 16 | ||||
Pack-years (continuous) | 0-2-27 | 0-15-43 | ||||
Comorbid conditions (%) | ||||||
Cardiovascular disease | 23 | 23 | 0.98 | |||
Diabetes | 16 | 16 | 0.91 | |||
Chronic obstructive pulmonary disease and other pulmonary diseases | 12 | 12 | 0.73 | |||
BMI | 24.1-27.0-30.2 | 24.2-27.1-30.7‡ | 0.71 | |||
Abdominal visceral fat area (cm2) | 93-129-178 | 99-138-183† | 0.08 | |||
Physical activity, kcal/wk (%) | ||||||
0-499.9 | 37 | 40 | 0.15 | |||
500-999.9 | 34 | 35 | ||||
≥1,000 | 29 | 25 | ||||
Medication use (%) | ||||||
NSAIDs | 23 | 18 | 0.04 | |||
Corticosteroids | 4 | 3 | 0.38 | |||
ACE inhibitors | 15 | 17 | 0.43 | |||
Statins | 12 | 14 | 0.34 |